Effectiveness and infectious complications of BCMA T‐cell engagers in treating multiple myeloma: Real‐world evidence from Sweden
Open Access
- 23 April 2024
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 13 (8) , e7048
Abstract
Background: Multiple myeloma (MM), an incurable disease characterized by frequent relapses and a need for multiple treatments, often progresses to a relapse/refractory status resistant to all available drugs and drug classes. Bispecific antibodies, specifically BCMA T‐cell engagers, have emerged as effective treatments for MM, demonstrating impressive efficacy. However, these treatments can adversely affect the immune system, increasing vulnerability to infections.Methods/Results: This study evaluated the efficacy and safety of BCMA T‐cell engagers in 58 Swedish patients with poor MM prognosis. The patients exhibited a 69% overall response rate, with 69% survival and 60% progression‐free survival at 15 months.Conclusions: Despite the risk of infectious complications, the prognosis of MM patients can be significantly improved with vigilant monitoring and proactive management of infections. This real‐world data highlight the potential of BCMA T‐cell engagers in treating MM, emphasizing the need for careful patient monitoring to mitigate infection risks.Keywords
This publication has 10 references indexed in Scilit:
- Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial resultsNature Medicine, 2023
- Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma NetworkThe Lancet Oncology, 2023
- Teclistamab in Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2022
- Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14)American Journal of Hematology, 2021
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapyLeukemia, 2019
- Infectious complications and NK cell depletion following daratumumab treatment of Multiple MyelomaPLOS ONE, 2019
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG studyLeukemia, 2017
- Infection risk with immunomodulatory and proteasome inhibitor–based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysisEuropean Journal of Cancer, 2016
- Cytomegalovirus reactivation in patients with multiple myelomaEuropean Journal of Haematology, 2015
- Proteasome inhibitors: antitumor effects and beyondLeukemia, 2006